Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab for Preventive Treatment of Chronic Migraine
2023-510183-12-00Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Eptinezumab (Vyepti) with Placebo (2 arms). Primary endpoint: Change from baseline in the number of monthly migraine days (MMDs). Started Apr 2024; status: completed.
02
Drugs
eptinezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2023-510183-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510183-12-00.